- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02187445
Inhaled Corticosteroid Use to Prevent Acute Chest Syndrome Recurrence in Children Between 1 and 4 With Sickle Cell Disease: a Feasibility Trial
February 16, 2017 updated by: Michael DeBaun, Vanderbilt University
Acute and chronic pulmonary complications with concomitant inflammatory response are a leading cause of morbidity and mortality in children with sickle cell disease (SCD).
Acute chest syndrome (ACS), defined broadly as an increase in respiratory effort, fever and new radiodensity on chest x-ray, is a major cause of death in children and adults with SCD.
There is a high rate of ACS in children between 1 and 4 years of age that is associated with an asthma diagnosis, and children with ACS events before 4 years of age have a 50% rate of being hospitalized for either ACS or pain within 1 year of admission.
For children with SCD that develop ACS, the investigators propose that the use of budesonide inhalation suspension (BIS) will attenuate pulmonary inflammation after an ACS episode and will decrease future vaso-occlusive pain and ACS episodes.
Through a single-arm prospective feasibility trial and in preparation for a limited-institution randomized trial, the investigators plan to test the following primary hypothesis for a phase III definitive trial: In children with SCD admitted to the hospital for an ACS episode between 1 and 4 years of age, low dose BIS for 6 months will result in a 50% reduction in the recurrent incidence rate of ACS or pain requiring hospitalization.
Through this trial, the investigators will determine the acceptability of and adherence to BIS in the study population.
The investigators will track respiratory symptoms in cases versus controls over 6 months.
Finally, the investigators will explore the impact of BIS on biological correlates (sVCAM-1).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
36
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232-9000
- Vanderbilt University Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 year to 4 years (CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 1) confirmed diagnosis of sickle cell disease (SCD)
- 2) age between 1 and 4 years (must have reached 1st but not yet 4th birthday)
- 3) a prior diagnosis of ACS, defined as acute respiratory illness with a new radiodensity on CXR, and one of the following: fever (temperature > 38.50C), decrease in oxygen saturation more than 3% from baseline, or increase in respiratory rate above baseline
Exclusion Criteria:
- 1) patients already taking inhaled corticosteroids
- 2) those receiving blood transfusions for elevated TCD or strokes
- 3) presents over 2 weeks after discharge from hospital following initial ACS episode.
Participants may be on hydroxyurea and participate in this trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Budesonide inhalation suspension
To determine the acceptability of budesonide inhalation suspension (BIS) 0.5 QD for 6 months for children with SCD that develop ACS between 1 and 4 years of age (n=10).
|
To determine the acceptability of budesonide inhalation suspension (BIS) 0.5 QD for 6 months for children with SCD that develop ACS between 1 and 4 years of age (n=10).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The acceptability of budesonide inhalation suspension
Time Frame: 6 Months
|
Specific Aim 1: To determine the acceptability of budesonide inhalation suspension (BIS) 0.5 QD for 6 months for children with SCD that develop ACS between 1 and 4 years of age (n=10).
We will determine the proportions of eligible families who were willing to participate and families that enrolled and elected to stay throughout the six months of the trial.
We will also assess adherence to BIS using the Morisky scale; this will be our primary outcome.
If the participation rate for the trial is less than 60%, the dropout rate is greater than 20%, or if our adherence rate is poor as measured by the Morisky scale, then alternative strategies for recruitment, retention and adherence must be considered.
|
6 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The impact of BIS on biological correlates of inflammation.
Time Frame: 12 weeks (or between 8-16 weeks) and at 24 weeks (or between 20-28 weeks)
|
Specific Aim 2: To explore the impact of BIS on biological correlates of inflammation.
For this purpose, a blood sample measurement will be taken at baseline, at 12 weeks (between 8-16 weeks) and at 24 weeks (between 20-28 weeks), as per routine clinic visits.
The research visit will be coordinated with the standard care visits and phlebotomy.
Soluble vascular cell adhesion molecule-1 (sVCAM-1), a marker of chronic vasculopathy, will be the primary measure of vascular injury.
Secondary outcome measures will include additional inflammatory markers (sP-selectin, sE-selectin, IL-1B, IL-6, TNFα, IFN-y, leukotrienes).
|
12 weeks (or between 8-16 weeks) and at 24 weeks (or between 20-28 weeks)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quality of life for guardians of children with sickle cell disease and ACS
Time Frame: 0 weeks, 12 weeks (or between 8-16 weeks) and at 24 weeks (or between 20-28 weeks)
|
At each clinic visit, we will also collect patient-centered outcomes, assessing caregiver burden.
Data will be collected using the Pediatric Asthma Caregiver's Quality of Life Questionnaire (PACQLQ), validated for parents of children with asthma.
|
0 weeks, 12 weeks (or between 8-16 weeks) and at 24 weeks (or between 20-28 weeks)
|
Respiratory symptoms
Time Frame: 6 months, monthly
|
Using the TRACK survey, validated for guardians of children under the age of 5 years, we will call families monthly to collect data on respiratory symptoms over the course of the study.
|
6 months, monthly
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2014
Primary Completion (ACTUAL)
December 1, 2016
Study Completion (ACTUAL)
February 13, 2017
Study Registration Dates
First Submitted
June 27, 2014
First Submitted That Met QC Criteria
July 10, 2014
First Posted (ESTIMATE)
July 11, 2014
Study Record Updates
Last Update Posted (ACTUAL)
February 17, 2017
Last Update Submitted That Met QC Criteria
February 16, 2017
Last Verified
February 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Respiratory Tract Diseases
- Respiration Disorders
- Lung Diseases
- Disease Attributes
- Disease
- Hematologic Diseases
- Genetic Diseases, Inborn
- Anemia
- Anemia, Hemolytic, Congenital
- Anemia, Hemolytic
- Hemoglobinopathies
- Syndrome
- Recurrence
- Anemia, Sickle Cell
- Acute Chest Syndrome
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Budesonide
Other Study ID Numbers
- DDCF2014086
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
SingHealth PolyclinicsNot yet recruitingAsthma | Asthma in Children | Asthma Attack | Asthma Acute | Asthma Chronic
-
Johann Wolfgang Goethe University HospitalCompleted
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
Clinical Trials on Budesonide inhalation suspension
-
Aquilon Pharmaceuticals S.A.Completed
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingChronic Obstructive Pulmonary Disease (COPD)China
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Recruiting
-
AllerganMAP Pharmaceuticals, Inc., a wholly owned subsidiary of AllerganCompleted
-
AstraZenecaCompletedAsthma | Chronic Obstructive Pulmonary Disease COPDUnited States
-
AstraZenecaParexelCompletedChronic Obstructive Pulmonary DiseaseUnited States
-
Liquidia Technologies, Inc.PPDRecruitingPulmonary Arterial Hypertension | Pulmonary Hypertension Due to Lung DiseasesUnited States
-
Vectura LimitedCompletedWheezing | Reactive Airway Disease | Mild AsthmaUnited States
-
Orion Corporation, Orion PharmaCompleted
-
AllerganMAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan; Q-Pharm Pty...Completed